Investor Relations
Latest Ad-Hoc Releases
- 2013/03/25
- SYGNIS announces Management Board changes
- 2013/03/04
- SYGNIS Pharma AG secures further financial resources with shareholder loan
- 2012/12/20
- SYGNIS announces the adaptation of its organisation to the new business activity
- 2012/10/17
- SYGNIS Pharma AG announces changes in Management Board
- 2012/09/24
- SYGNIS Pharma AG / Genetrix Life Sciences, A.B., and Genetrix, S.L., Granted Exemption from Mandatory Tender Offer to Shareholders of SYGNIS Pharma AG
- 2012/09/06
- SYGNIS announces intended changes in the Supervisory Board
- 2012/07/31
- SYGNIS Announces Prolongation of Standby Equity Distribution Agreement
- 2012/07/18
- SYGNIS Announces Proposed Combination of Business with GENETRIX’ subsidiary X-Pol
- 2012/06/29
- SYGNIS announces acquisition of a loan from BASF SE
- 2011/12/15
- SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the treatment of Acute Ischemic Stroke
- 2011/08/10
- SYGNIS Pharma AG successfully completes capital increase
- 2011/07/20
- SYGNIS Pharma AG decides on increase in share capital
- 2011/06/15
- SYGNIS Pharma AG secures further financial resources with shareholder loan
- 2010/10/29
- SYGNIS Pharma AG announces strategic restructuring
- 2010/10/28
- Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG
- 2009/10/19
- SYGNIS secures up to € 10 Million through a 3 year Standby Equity Distribution Agreement with Yorkville
- 2008/11/14
- SYGNIS Pharma AG receives mandatory offer of dievini Hopp BioTech holding GmbH & Co. KG
- 2008/10/15
- SYGNIS Pharma AG Approves Capital Increase
- 2008/06/08
- SYGNIS announces agreement on acquisition of Amnestix Inc.
- 2007/07/22
- SYGNIS announces successful completion of the clinical IIa study for AX200 in stroke (AXIS)
Latest Press Releases
-
May 16, 2013
:
SYGNIS licenses amplification buffer to QIAGEN QIAGEN
-
May 15, 2013
:
SYGNIS reports results for the first quarter of 2013